Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Abstract

The aprepitant regimen was more effective than the control regimen for prevention of CINV in patients receiving both an anthracycline and cyclophosphamide.

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

“…Nausea has not been signifcantly improved by the use of fosaprepitant (aprepitant) in 2 phase 3 studies of patients receiving cisplatin 22,23 and in 2 phase 3 studies of patients receiving an anthracycline and cyclophosphamide chemotherapy regimen. 24,25 Two reviews on the prevention of chemotherapy-induced nausea concluded that NK-1 receptor antagonists are not efective in controlling nausea. 10,26 Te data from the currently reported trial and the others, noted above, support National Comprehensive Cancer Network guidelines, which list the olanzapine, palonosetron, and dexamethasone regimen as an optional frst-line therapy for the prevention of CINV in patients receiving HEC and MEC.…”

5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

“…Moreover, not all oncologists are comfortable with prescribing more than one dose of dexamethasone for several days after chemotherapy. 25 In view of the ease of availability, low cost, and evidence for the efficacy of dexamethasone for control of chemotherapy-related nausea and vomiting, a study to clarify it's the role in the delayed phase is needed.…”

Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?

“…[17] The efficacy of NK-1 RA is achieved especially in the delayed phase of CINV. [18][19][20] The most common side effects of aprepitant are headache, anorexia, diarrhea, hiccups, fatigue, and a mild elevation of serum transaminase levels. [21] Aprepitant is a moderate inhibitor and an inducer of cytochrome P450 (CYP) 3A4, as well as an inducer of CYP2C9.…”